Navigation Links
Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007

DURHAM, N.C.--(BUSINESS WIRE)--May 4, 2007 - Argos Therapeutics today announced the presentation of data on the immunosuppressive properties of soluble CD83 at the 7th Joint American Transplant meeting to be held in San Francisco, May 5-9. The presentations will be made in collaboration with scientists at the University of Western Ontario.

"These data suggest that soluble CD83 is able to extend graft survival in transplantation, and that it can also act synergistically with other immunosuppressive agents," commented Dr. Stephen Brand, Director of Biotherapeutics at Argos Therapeutics. "sCD83 appears to be able to maintain antigen presenting cells in an immature state, and these immunologically tolerant cells favor regulatory T-cell generation because they are less effective in activating naive T and B cells."

"This emerging activity profile for sCD83, as well as its ability to suppress antibody production without systemic suppression, may provide advantages over currently available B-cell targeting therapies," said Dr. Charles Nicolette, Chief Scientific Officer and Vice President of Research and Development of Argos. "The extended graft survival that we have observed thus far indicates that sCD83 could potentially provide enhanced organ function, without immune rejection, and may serve to reduce the toxic profile associated with many commonly used immunotherapeutic agents. These data support Argos' plans to conduct additional studies with CD83 in transplantation and autoimmune models, which will provide important information as we develop a clinical strategy for this candidate."

Data will be discussed in the following presentations:

-- Abstract # 1697: "Soluble CD83 in combination with Rapamycin and anti-CD45RB monoclonal antibody induces long-term graft survival in a mouse cardiac transplantation model"

-- Abstract #116: "Soluble CD83 can inhibit B-cell activation and differentiati
'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:7/28/2015)... , July 28, 2015 Voalte, the ... global leader in purpose-built wireless communications, today announced ... Regional), a 104-bed acute-care facility in ... the Voalte One™ solution on Spectralink PIVOT™ purpose-built ... Spectralink named Voalte a member of its AIMS ...
(Date:7/28/2015)... 28, 2015 Egalet Corporation (Nasdaq: ... company focused on developing, manufacturing and marketing innovative ... underwritten public offering of 6,666,667 shares of its ... $11.25 per share. The gross proceeds to Egalet ... $75 million, before deducting the underwriting discounts and ...
(Date:7/28/2015)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) launched its ... (AACC) 2015 Clinical Lab Expo today by introducing ... educational initiative that demonstrates how Roche is partnering ... laboratory. The new LabLeaders initiative ( ... the people within them through insight from industry ...
Breaking Medicine Technology:Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 2Bay Area Regional Medical Center Is First to Use Spectralink PIVOT with Voalte One for Caregiver Communication 3Egalet Announces Pricing of Public Offering of Common Stock 2Egalet Announces Pricing of Public Offering of Common Stock 3Egalet Announces Pricing of Public Offering of Common Stock 4Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 2Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 3Roche introduces LabLeaders educational initiative to help redefine the value of the laboratory at AACC 2015 Clinical Lab Expo 4
... , TAI,AN, China, ... (Nasdaq: CBPO ) ("China Biologic," or,the "Company"), one of the ... received approval to list its,common stock on the NASDAQ Global Market. ... begin trading on the NASDAQ on,Wednesday, December 2, 2009, until which ...
... SAN DIEGO, Dec. 1 ADVENTRX Pharmaceuticals, Inc. (NYSE ... recently completed preclinical study has affirmed the bioequivalence and ... Poong Pharmaceuticals, ADVENTRX,s partner for ANX-514 in South Korea, ... , "Our independent confirmation of the bioequivalence and comparable ...
Cached Medicine Technology:China Biologic Products Approved to List on NASDAQ 2China Biologic Products Approved to List on NASDAQ 3ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 2ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514 3
(Date:7/28/2015)... Nashville, Tenn. (PRWEB) , ... July 28, 2015 ... ... has added the SmileCareClub Invisible Aligner System to its online product ... , By using a teledentistry model and cloud-based technology, SmileCareClub allows patients to ...
(Date:7/28/2015)... Wayne, PA (PRWEB) , ... July 28, 2015 ... ... that its Board of Directors has authorized the Company, from time to time ... with an aggregate value of up to $25 million. Repurchases will be made ...
(Date:7/28/2015)... (PRWEB) , ... July 28, 2015 , ... ... services to include a proprietary, web based clinical knowledge system, called “Referral Guidance.” ... evidence based. It provides physicians who are anticipating making a subspecialty referral ...
(Date:7/28/2015)... ... 2015 , ... Fertility specialist Dr. Lisa Hasty of Atlanta Center ... Magazine. In Atlanta Magazine's annual Top Doctors issue, Dr. Hasty has been recognized for ... in the metro area as one of the most respected doctors in Reproductive Endocrinology. ...
(Date:7/28/2015)... ... July 28, 2015 , ... A new study published ... Fibromyalgia, Study Says " sheds light on a possible new treatment option for people ... months of regular HBOT sessions, at least five per week, patients experienced a significant ...
Breaking Medicine News(10 mins):Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 2Health News:Brookstone Now Offers SmileCareClub Teeth Straightening System 3Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 2Health News:Safeguard Scientifics Board of Directors Authorizes up to $25 Million Share Repurchase Program 3Health News:Introducing Care to Care’s New Web Based “Referral Guidance” Program 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 2Health News:Atlanta Fertility Specialist Named Top Doctor in Atlanta Magazine 3Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 2Health News:Recovery Specialists Discuss How Oxygen Therapy Can Ease Fibromyalgia 3
... - Region,s Fastest Growing Private Company* Delivers Quality, ... in Patients, Needs -, GLENDALE, Calif., Nov. ... (2005 through 2007) earned it the status as ... the region,s top business media,Lakeside Systems, Inc. (Lakeside) ...
... Increases Fund Size for Venture Team by 30%, ... Ventures (, http://www.morgenthaler.com/ventures ), a leading venture ... today that it has exceeded its,fundraising goal and ... $400,million. This brings the firm,s total capital under ...
... PLC Systems Inc.,(Pink Sheets: PLCSF), a company ... today stated that, following the,delisting of its common ... Stock Exchange) on Monday, November 10, 2008, the ... its common stock listing to the,OTCBB. Until that ...
... articles that stress African-American health disparities, like higher ... black patients from being screened for cancer, according ... are more likely to be tested for cancer ... among African-American cancer patients. , While the medical ...
... International Conference on Wireless ... Identification in Milan, HATBORO, Pa., ... of enterprise mobility and advanced,wireless asset tracking solutions for the healthcare ... on the predictive value of identification technology at the ID,WORLD International ...
... Closed in 2008, According to New Report,from HealthLeaders-InterStudy, ... provider of managed care market intelligence, reports that ... better than health systems,in other parts of the ... to the new Southern New Jersey Market Overview, ...
Cached Medicine News:Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 2Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 3Health News:Lakeside Systems, Inc. Unifies Integrated Healthcare Delivery System under New Brand: Lakeside Community Healthcare 4Health News:Morgenthaler Closes Ninth Fund at $400 Million 2Health News:Morgenthaler Closes Ninth Fund at $400 Million 3Health News:Morgenthaler Closes Ninth Fund at $400 Million 4Health News:PLC Systems Updates Common Stock Listing Status 2Health News:Messages of hope work better in motivating black patients to seek early screening for cancer 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 2Health News:InfoLogix CEO to Address Hidden Value of ID Technology at International Conference 3Health News:Southern New Jersey Hospitals Thriving, but Cautious in Light of Market Conditions 2Health News:Southern New Jersey Hospitals Thriving, but Cautious in Light of Market Conditions 3
...
Ascent Primary Knee System with cruciate retaining, posterior stabilized and constrained components...
... solution tricompartmental total knee prosthesis stems from ... State-of-the-art design and manufacturing technologies have been ... function as well as a favorable pressure ... to keep wear to a minimum. The ...
... system continues the "Consensus Concept" approach to ... diversified experience of a Scientific Advisory Board. ... that incorporates state-of-the-art features. Consensus Knee implants ... implant stability and allow near normal kinematics. ...
Medicine Products: